ORIGYN-FOUNDATION
23.11.2021 15:40:13 CET | Business Wire | Press release
ORIGYN Foundation , the Swiss nonprofit dedicated to identifying, authenticating and unlocking the powers of ownership for objects of value, has today announced a strategic raise of $20 million. Investors in this round include Bill Ackman’s Table Management, Polychain Capital, Paris Hilton, Coinko, Vectr Ventures, Carter Reum, Div Turakhia, GD10 Ventures and more. Ahead of the foundation’s public token release, this private round now values ORIGYN at $300 million.
“We’re incredibly fortunate and excited to include so many influential names in this funding round. ORIGYN is unique in what it brings to this world. It’s a sign of support for what ORIGYN is trying to achieve—using technology to solve for identity, authenticity and proof of ownership. Our partners have seen the opportunity we provide to unlock value for owners and creators,” said Daniel Haudenschild, CEO of ORIGYN Entreprise SA, which is the operating entity of ORIGYN Foundation.
Founded in October of 2020, ORIGYN is led by its founding partners and council members Gian Bochsler, Vincent Perriard and Mike Schwartz, as well as by CEO Daniel Haudenschild. The foundation’s technology certifies and guarantees the authenticity of physical and digital items using advanced recognition and identification techniques created by leading experts in computer vision, artificial intelligence and decentralized infrastructure. It also unites the greatest contemporary players across select industries to protect, celebrate, elevate and reward creativity through its novel approach to NFTs.
ORIGYN currently operates the following industry verticals:
● ORIGYN Art is an exclusive community for the fine art market on the blockchain. This vertical establishes a connection between physical works of art and NFT certificates to create the ultimate marketplace experience for creators, industry professionals, collectors and enthusiasts.
● ORIGYN Collectibles is a revolutionary platform designed to empower individuals with shared passions to buy, sell, trade and experience collectors’ items. This vertical rewards and celebrates creativity by tokenizing certificates of ownership that verify the uniqueness and authenticity of physical collectibles.
● ORIGYN Digital Media is a comprehensive ecosystem built for media creators of all types to activate their social capital. This vertical provides tooling for all forms of experiential content, artifacts and marketplaces for the world’s most creative icons and their fans.
● ORIGYN Luxury is the only digital certification solution guaranteed to prove authenticity using a luxury object’s own biometric features. These digital certificates increase trust between companies and their clients with a paperless solution, guaranteed by ORIGYN, which facilitates the resale of the object. This vertical brings NFTs to life by enabling the object itself to become its own proof of authenticity.
Funding from this round powers the foundation’s mission and contributes to the expansion and continuous improvement of ORIGYN’s verticals as directed by governing token holders. Additionally, it will be used to fund ongoing R&D and onboard the foundation’s growing list of industry partners to the ecosystem.
The ORIGYN authentication platform far surpasses other NFT certification solutions in the market today due to the unique biometric and ownership data included in ORIGYN digital twins, as well as the global guarantee that backs every digital certificate. ORIGYN will officially launch these digital certificates across industry verticals during the first half of 2022. The foundation’s utility token, OGY, will also become publicly tradable in 2022. OGY is necessary to engage with the core services of the platform and is used to create and transact certificates of authenticity.
About the ORIGYN Foundation:
The Swiss non-profit foundation ORIGYN uses intelligent technologies, including computer vision and artificial intelligence, on decentralized computing to identify, authenticate and unlock the powers of ownership for objects of value. As the first digital certification platform built on the Internet Computer (IC), ORIGYN and its verticals generate new forms of value for some of the largest consumer asset classes in the world, including art, collectibles, digital media and luxury goods. Founded in Neuchâtel, Switzerland in October of 2020, ORIGYN operates globally in major technology and blockchain hubs around the world. For more information, visit origyn.ch .
ORIGYN Foundation: Website Twitter LinkedIn Facebook Medium
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005882/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom